date:May 25, 2012
o major omega-3 cardio drugs due to come off patent at the end of the year.
Both companies acknowledged pharma applications played a part in the acquisition decisions (Equateq and Ocean Nutrition Canada respectively), whilst not discounting the importance of the food-supplement space.
Look for a video interview with Michael Ceranski, the BASF senior vice president, global business unit, human nutrition, on that and the units strategy in coming days.
DSM warned it was considering action over p